arbaclofen-placarbil and isobutyric-acid

arbaclofen-placarbil has been researched along with isobutyric-acid* in 1 studies

Other Studies

1 other study(ies) available for arbaclofen-placarbil and isobutyric-acid

ArticleYear
Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.
    The Journal of pharmacology and experimental therapeutics, 2009, Volume: 330, Issue:3

    Baclofen is a racemic GABA(B) receptor agonist that has a number of significant pharmacokinetic limitations, including a narrow window of absorption in the upper small intestine and rapid clearance from the blood. Arbaclofen placarbil is a novel transported prodrug of the pharmacologically active R-isomer of baclofen designed to be absorbed throughout the intestine by both passive and active mechanisms via the monocarboxylate type 1 transporter. Arbaclofen placarbil is rapidly converted to R-baclofen in human and animal tissues in vitro. This conversion seems to be primarily catalyzed in human tissues by human carboxylesterase-2, a major carboxylesterase expressed at high levels in various tissues including human intestinal cells. Arbaclofen placarbil was efficiently absorbed and rapidly converted to R-baclofen after oral dosing in rats, dogs, and monkeys. Exposure to R-baclofen was proportional to arbaclofen placarbil dose, whereas exposure to intact prodrug was low. Arbaclofen placarbil demonstrated enhanced colonic absorption, i.e., 5-fold higher R-baclofen exposure in rats and 12-fold higher in monkeys compared with intracolonic administration of R-baclofen. Sustained release formulations of arbaclofen placarbil demonstrated sustained R-baclofen exposure in dogs with bioavailability up to 68%. In clinical use, arbaclofen placarbil may improve the treatment of patients with gastroesophageal reflux disease, spasticity, and numerous other conditions by prolonging exposure and decreasing the fluctuations in plasma levels of R-baclofen.

    Topics: Animals; Baclofen; Binding, Competitive; Butyrates; Carboxylesterase; Carboxylic Ester Hydrolases; Cells, Cultured; Chemistry, Pharmaceutical; Cytochrome P-450 Enzyme System; GABA Agonists; Humans; Hydrolysis; Intestinal Absorption; Isobutyrates; Isoenzymes; LLC-PK1 Cells; Male; Membranes, Artificial; Oocytes; Prodrugs; Rats; Rats, Sprague-Dawley; Tissue Distribution; Wine

2009